Cingulate (CING) Registration filing summary

Company overview and business model

• Biopharmaceutical company leveraging proprietary Precision Timed Release (PTR) technology to develop next-generation pharmaceuticals targeting conditions with burdensome dosing and suboptimal outcomes, initially focusing on ADHD and anxiety.

• Pipeline includes CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for ADHD, and CTx-2103 (buspirone) for anxiety, aiming to provide true once-daily dosing and improved patient outcomes.

• PTR platform uses a proprietary Erosion Barrier Layer to enable controlled, multi-dose release in a single tablet.

Financial performance and metrics

• As of March 13, 2026, 11,594,679 shares of common stock were outstanding; up to 3,500,000 additional shares may be issued in this offering.

• The company qualifies as an emerging growth company with less than $1.235 billion in annual revenue and benefits from reduced reporting requirements.

• Audit report notes substantial doubt about the company's ability to continue as a going concern due to losses and negative cash flows.

Use of proceeds and capital allocation

• Proceeds from sales to Lincoln Park will be used for regulatory approval, development, manufacturing, and commercialization of CTx-1301, as well as working capital, capital expenditures, and general corporate purposes, including further R&D.

• Management has broad discretion over the use of proceeds, which may also be invested in complementary businesses or technologies.